Evercore ISI lowered the firm’s price target on Moderna (MRNA) to $50 from $60 and keeps an In Line rating on the shares. The firm is updating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback